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Abstract
Objective: Maintenance hemodialysis (MHD) patients often have impaired quality of life (QOL), anxiety, depression, and reduced
daily physical activity (DPA) and physical performance. The contributions of these latter factors to reduced QOL in MHD are
poorly understood. We examined the association of QOL with anxiety, depression, DPA, and physical performance.
* Corresponding author. Los Angeles Biomedical Research Institute, Harbor e UCLA Medical Center, 1124 West Carson Street, Torrance, CA
90502, USA.
E-mail address: jkopple@labiomed.org (J.D. Kopple).
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Methods: Seventy-two relatively healthy adult MHD patients, vintage 6 months, and 39 normals of similar age range and gender
distribution were studied. QOL was assessed using the Kidney Disease Quality of Life-Short Form (KDQOL-SF). Anxiety and
depression were each evaluated with two questionnaires. DPA and physical performance were assessed with a physical activity
monitor, Human Activity Profile, and 6-minute walk, sit-to-stand, and stair-climbing tests.
Results: Most KDQOL components were reduced in MHD patients versus normals. KDQOL components in patients were
commonly inversely correlated with measures of anxiety and depression (P < 0.05) and were more reduced in patients with both
anxiety and depression. KDQOL was often impaired in patients with either anxiety or depression. However, most KDQOL scores
did not differ between patients and normals without anxiety or depression. DPA, Human Activity Profile, and physical performance often correlated with KDQOL scores in adjusted models, but after further adjustment for anxiety and depression, DPA,
Human Activity Profile, and physical performance correlated less frequently with KDQOL scores. This reduction in significant
correlations after adjustment for anxiety and depression was particularly pronounced for the association between KDQOL and
DPA.
Conclusion: In relatively healthy MHD patients, KDQOL scores are usually decreased in those with anxiety and/or depression but
are usually normal in those without anxiety or depression. Lower DPA in MHD patients with reduced KDQOL scores often appears
to be associated with anxiety and depression. The relationship between QOL and physical performance appears to be less influenced by anxiety and/or depression. These data suggest that treatment of anxiety and depression in MHD patients may improve
their QOL, DPA, and possibly physical performance.
© 2016 Chinese Medical Association. Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords: Quality of life; Anxiety; Depression; Kidney disease; Kidney failure

Introduction

Methods

Maintenance hemodialysis (MHD) patients
frequently experience reduced quality of life (QOL)
and have decreased daily physical activity (DPA) and
physical performance.1e4 Many reports indicate that
anxiety and/or depression are associated with a
reduction in their QOL and with reduced DPA and
physical performance.3,5e9 An important question is
whether the direct relation between QOL scores and
DPA and physical performance may be mediated by
anxiety or depression in MHD patients. This question
may have important clinical implications, because
reduced DPA and physical performance as well as
depression are associated with increased hospitalizations and enhanced mortality rates.10e15 As part of
ongoing studies of the effects of altered physical capacity in MHD patients, we conducted a crosssectional study of the frequency and severity of
impaired QOL scores and their relationship with DPA
and physical performance. We assessed the extent to
which anxiety and depression in MHD patients may
account for both their impaired QOL and to the
interaction of DPA and physical performance with
QOL. A cohort of relatively healthy MHD patients
was selected for study in order to minimize the confounding effects of comorbid conditions, which occur
commonly in these individuals and can lower their
QOL.

Study methods have been described in detail previously2,4 and are summarized here.
Study design and participants

Inclusion criteria included the following: (1) age,
18 years; (2) no hospitalizations during the previous
3 months, except for vascular access repair; (3) no
amputations or prostheses in lower extremities; (4)
able to ambulate and ability to complete all study
protocol tests; and (5) likelihood of good compliance
to the protocol. Exclusion criteria included the
following: (1) acute infectious or other inflammatory
illnesses; (2) current heart failure, lung failure, severe
liver disease, or active cancer except basal cell carcinoma; and (3) myocardial infarction or angina
pectoris within the past 12 months. Almost all MHD
patients were recruited from two DaVita Corporationowned chronic dialysis centers in the South Bay area
of Los Angeles County. At the time of study, these
two centers were treating 335 MHD patients. Normal
controls were of similar age range and gender distribution and had no known acute or chronic systemic
illnesses or disorders of the extremities that could
impede mobility or other physical activities. The
normal controls denied participating in regular sports
activities.
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This was a cross-sectional, non-interventional
study. All participants made one visit to the Outpatient Clinical Translational Research Center (for hemodialysis patients, on the day after a hemodialysis
treatment) where they underwent a 6-minute walk
test (6-MWT), and sit-to-stand and stair-climbing
tests, and filled out questionnaires. Collection and
processing of blood specimens have been described
previously.4 The study was approved by the institutional review boards of the Los Angeles Biomedical
Research Institute at HarboreUCLA Medical
Center. All participants signed informed consent
statements.
QOL assessment

QOL was assessed in MHD patients and normal
controls using the Kidney Disease and Quality of
Life-Short Form (KDQOL-SF) (KDQOL Working
Group, RAND Corporation, Santa Monica, CA,
USA).16 The questionnaire consists of the generic
36-Item Short Form Health Survey (SF-36) as well
as 11 multi-item scales focusing on quality of life
issues specific to patients with kidney disease (endstage renal disease (ESRD)-targeted areas).17,18
Thirty-five items of the SF-36 are organized into 8
quality of life dimensions. One item, self-reported
health transition, is not considered relevant to these
8 dimensions. The SF-36 produces 2 summary
measures of physical and mental health: the physical
health composite score and mental health composite
score.19 There are 11 items comprising the ESRDtargeted areas of the KDQOL. KDQOL scales are
assessed quantitativelyda score between 0 and 100
is calculated with higher scores reflecting better
health and well-being. In MHD patients, the KDQOL
was administered on the same day as the physical
performance tests after completion of these physical
performance tests.
Anxiety and depression questionnaires

Participants completed the Beck Anxiety Inventory
(BAI), the Beck Depression Inventory (BDI)-II, and
the Hospital Anxiety and Depression Scale (HADSanxiety and HADS-depression).20 The BAI is a 21item self-report inventory for assessing severity of
clinical anxiety. Respondents rate each item on a 4point scale ranging from 0 (“Not at all”) to 3 (“I
could barely stand it”) with regard to their anxietyrelated symptoms during the past week. The BAI is
scored by summating the severity ratings across all 21

items; total scores can range from 0 to 63. Scores are
considered to indicate the following: 0e7, minimal
anxiety; 8e15, mild anxiety; 16e25, moderate anxiety; 26e63, severe anxiety. Similarly, the BDI is a 21item inventory to measure severity of depressive
symptoms.21 All items are rated from 0 to 3, and
respondents are asked to rate their depressive symptoms during the previous two weeks. The BDI total
scores can range from 0 to 63. BDI scores are
considered to indicate the following: 0e13, minimal
depression; 14e19, mild depression; 20e28, moderate depression; 29e63, severe depression. The
HADS-anxiety and HADS-depression were also used
to assess symptoms of anxiety and depression.22 This
questionnaire comprises 14 items divided into two
parts for rating anxiety and depression. Each item has
a 4-response category range from 0 to 3. The scale
ranges from 0 to 21 for both depression and anxiety.
For both anxiety and depression scores, 0e7 is
considered normal, 8e10 borderline abnormal, and
11e21 abnormal.22
DPA

DPA was assessed with a physical activity monitor
(Actigraph GT3Xþ Activity Monitor®, Actigraph,
Fort Walton Beach, FL, USA) that was strapped to
the lateral side of the pelvis on the non-dominant
side of the hips.4 The activity monitor was worn
continuously for 10 days, including nights, except
when participants took baths, showered, or swam.
Physical activity levels were calculated during the
last 7 full days of activity. The average daily vector
magnitude for DPA was calculated as the square root
of the sum of the squares of the movement readings
from each of the three dimensional axes. We classified activity level as sleep or marked physical inactivity (i.e., vector magnitude of 0e500), light
physical activity (vector magnitude of 501e2689),
and moderate or greater physical activity (vector
magnitude 2690).4,23
All participants completed the Human Activity
Profile questionnaire, in which the person describes
how frequently he/she performs physical activities
requiring various amounts of energy expenditure and
intensities of physical performance.24 The Human
Activity Profile is calculated as a maximum activity
score which indicates the value of the highest
oxygen-demanding activity for each type of activity
listed in the questionnaire that the subject states that
he/she still performs. The Human Activity Profile
adjusted activity score is the respondent's maximum
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activity score minus the number of activities that the
person indicates that he/she can no longer perform.
These scores are considered to estimate, respectively,
their highest level of energy expenditure (the
maximum activity score) and average level of energy
expenditure (the adjusted activity score).4

for anxiety and depression status. A P-value of <0.05
was considered to indicate statistical significance.

Physical performance tests

MHD patients were 52 ± 13 years, 32% female, and
40% diabetic, with a dialysis vintage of 54 ± 45
months. Normal controls were 51 ± 13 years and 41%
female. Seven MHD patients had a history of depression, and there was no history of schizophrenia in
either group. The racial/ethnic distribution was similar
in both groups, but there was a trend for the MHD
patients to have less formal schooling. Body mass
index in MHD patients was (27.8 ± 5.8) kg/m2 and did
not differ significantly from normal controls
((27.0 ± 3.9) kg/m2). Serum albumin in both groups
was 4.1 g/dl. Blood hemoglobin in MHD patients was
(11.2 ± 0.8) g/dl and (13.8 ± 1.3) g/dl in normal
controls, and serum creatinine was (10.5 ± 4.3) mg/dl
predialysis in MHD patients as compared to
(0.8 ± 0.2) g/dl in normals. The Charlson comorbidity
score was 1.7 ± 1.1 in normal controls and 5.7 ± 2.7 in
MHD patients. This number includes two points for
kidney failure in each MHD patient plus two additional
points for MHD patients who have diabetes mellitus.25,26 Comparisons between these 72 MHD patients
and 39 normal controls have been described in greater
detail in previous reports.2,4
Several measurements of DPA, assessed by the
Actigraph® and Human Activity Profile maximum
activity score (MAS), and adjusted activity score
(AAS), and the 6-MWT, sit-to-stand, and stairclimbing test results were reduced in MHD patients
as compared to normal controls (P < 0.0001 for each
comparison).4 BAI, BDI, and HADS scores indicated
increased frequency and severity of anxiety and
depression in MHD patients.2

The three physical performance tests were conducted in the following order: 6-MWT, sit-to-stand,
and stair-climbing test. The 6-MWT measured the
distance (meters) that participants walked back and
forth along an 80-foot (24.4 m) horizontal corridor
during a 6-min period of time while they were
repetitively encouraged to walk fast. Study participants could slow down, rest, or even stop walking if
they wished, but the 6-min timer was kept running. In
the sit-to-stand test, participants rose from a fully
seated position to full standing and then returned to
the starting fully seated position as frequently as
possible, with encouragement, during a 30s period.
This test measured the number of sit-to-stand cycles
completed in 30 s. The stair-climbing test measured
the time (seconds) for participants to climb 22 steps as
fast as possible, again with encouragement, without
running, jumping, or skipping steps. The 6-MWT was
performed once, the sit-to-stand and stair-climbing
tests were each performed twice at 5-min intervals,
and the better of the two scores was selected for
analysis. Participants underwent these physical performance tests after they received a detailed explanation and demonstration of each test by a trained
examiner.
Statistical analyses

Statistical analyses were performed using STATA 12
statistical software (StataCorp LP, College Station, TX,
USA). Variables were expressed as mean ± standard
deviation (SD) and were compared between MHD and
normal control group by a Student's t-test for independent samples. Categorical variables of  three groups
were compared using a one-way analysis of variance
(ANOVA). Comparisons within multiple groups were
made using a Tukey's honest significant difference test
for pairwise comparisons. Comparisons between two
groups were made using a 2-tailed t-test. Four covariates were adjusted for in case-mix analyses: age,
gender, presence of diabetes mellitus, and dialysis
vintage. In some cases, analyses were further adjusted

Results
Participant characteristics

KDQOL scores
The KDQOL SF-36 component scores were
significantly lower (P < 0.05) in MHD patients as
compared to normal controls, except for two componentsdemotional well-being and mental health composite score, which did not differ between the two
groups (Table 1). The KDQOL ESRD-targeted
component scores were also significantly lower in
MHD patients, except for quality of social interaction
and social support (Table 1).
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Table 1
KDQOL component scores in MHD patients (versus normal controls) and their correlations with anxiety and depression scores.
KDQOL components

ESRD-targeted areas
Symptom problem list
Effects of kidney disease
Burden of kidney disease
Work status
Cognitive function
Quality of social interaction
Sexual functione
Sleep
Social support
Dialysis staff encouragement
Patient satisfaction
SF-36 composite scores
Physical health composite score
Mental health composite score
Role physical
Pain
General health
Emotional well-being
Role emotional
Social function
Energy/fatigue

MHD patients Normal controls Correlations with KDQOL in MHD patients
(n ¼ 72)
(n ¼ 39)
BAI
BDI
HADS-Anxiety
(n ¼ 72)
(n ¼ 72)
(n ¼ 72)
79.9
65.0
43.2
30.6
82.2
82.1
77.9
60.6
81.5
76.2
73.8

±
±
±
±
±
±
±
±
±
±
±

16.3a
25.9
27.6
38.0a
18.2a
18.2
29.3a
21.9a
26.5
23.4
23.4

95.8
e
e
82.1
91.3
87.9
95.3
78.3
86.9
e
e

±
±
±
±
±
±

26.9
10.7
11.7
10.3
13.8
14.3

40.4
50.6
44.8
74.4
51.3
79.1
70.8
71.9
56.7

±
±
±
±
±
±
±
±
±

9.5a
10.2
43.2a
26.6f
20.6a
17.5
41.8a
24.7a
22.2a

53.0
53.7
90.4
86.0
75.6
82.6
93.2
91.0
74.4

±
±
±
±
±
±
±
±
±

4.8
6.9
23.4
20.7
15.9
15.9
21.9
12.5
14.3

± 4.4

HADS-Depression
(n ¼ 72)

0.59b,c (0.56c)
0.35c (0.35c)
0.22 (0.21)
0.08 (0.01)
0.38c (0.33c)
0.27d (0.24d)
0.03 (0.19)
0.56c (0.58c)
0.28d (0.32c)
0.25d (0.22)
0.24d (0.24d)

0.47c (0.42c)
0.67c (0.58c)
0.48c (0.41c)
0.21 (0.14)
0.48c (0.39c)
0.40c (0.32c)
0.62c (0.59c)
0.59c (0.60c)
0.46c (0.51c)
0.34c (0.33c)
0.35c (0.35c)

0.46c (0.42c)
0.46c (0.42c)
0.44c (0.45c)
0.18 (0.10)
0.57c (0.52c)
0.45c (0.39c)
0.32 (0.36)
0.46c (0.48c)
0.31c (0.34c)
0.20 (0.15)
0.33 (0.33c)

0.41c (0.40c)
0.54c (0.52c)
0.59c (0.58c)
0.03 (0.06)
0.55c (0.54c)
0.37c (0.34c)
0.42d (0.38)
0.35c (0.33c)
0.35c (0.35c)
0.26d (0.27d)
0.35c (0.35c)

0.42c (0.40)c
0.37c (0.34)c
0.20 (0.18)
0.48c (0.44c)
0.34c (0.28d)
0.46c (0.42c)
0.20 (0.18)
0.47c (0.44c)
0.47c (0.45c)

0.30d (0.22)
0.60c (0.58c)
0.29d (0.22)
0.30d (0.22)
0.54c (0.48c)
0.69c (0.66c)
0.39c (0.33c)
0.57c (0.56c)
0.53c (0.51c)

0.29d (0.28d)
0.62c (0.62c)
0.24d (0.21)
0.35c (0.30c)
0.48c (0.45c)
0.67c (0.64c)
0.39c (0.37c)
0.60c (0.59c)
0.50c (0.50c)

0.27d (0.26d)
0.56c (0.56c)
0.28d (0.25d)
0.19 (0.16)
0.41c (0.39c)
0.64c (0.64c)
0.37c (0.34c)
0.57c (0.57c)
0.54c (0.54c)

Data are presented as mean ± standard deviation.
KDQOL: Kidney Disease and Quality of Life; MHD: maintenance hemodialysis; BAI: Beck Anxiety Inventory; BDI: Beck Depression Inventory;
HADS: Hospital Anxiety and Depression Scale; ESRD: end-stage renal disease; SF-36: 36-Item Short Form Health Survey.
a
P < 0.01 vs. normal controls as compared by a student's t-test for independent samples.
b
Correlation coefficients not in parentheses are unadjusted. Correlation coefficients in parentheses are adjusted for age, gender, presence of diabetes
mellitus, and dialysis vintage.
c
P < 0.01, d0.01  P < 0.05 in correlations between KDQOL component score and anxiety or depression score in MHD patients.
e
n ¼ 30 and n ¼ 24 respondents for sexual function component in MHD patients and normal controls, respectively.
f
0.01  P < 0.05 vs. normal controls as compared by a student's t-test for independent samples.

Association of anxiety and depression scores with
KDQOL
The BAI, BDI, HADS-anxiety, and HADS-depression scores were significantly and inversely correlated
with almost every KDQOL, ESRD and SF-36
component score in both unadjusted and case-mix
adjusted analyses (Table 1). As an example, the
scores from the above anxiety and depression questionnaires were inversely correlated (P < 0.05) with the
physical health composite score and mental health
composite score, where a lower physical health composite score or mental health composite score indicated
a poorer quality of life score. The only exception was
the correlation of the BDI score with the physical
health composite score which was significant in unadjusted models but significant only at 0.05 < P < 0.10
with case-mix adjustment (Table 1).

A one-way ANOVA compared KDQOL scores
among MHD patients who exhibited anxiety, depression, both anxiety and depression, or neither anxiety nor
depression, as determined by their BAI and BDI scores
(Table 2). The diagnosis of anxiety was made when their
BAI score was 8, and the diagnosis of depression was
made when their BDI score was 14. Analyses were
adjusted for age, gender, diabetes, and dialysis vintage.
MHD patients without either anxiety or depression had
significantly higher (more normal) scores for many
KDQOL and SF-36 components than MHD patients
with both anxiety and depression (Table 2). Patients
without anxiety or depression not uncommonly had
significantly higher KDQOL or SF-36 scores as
compared to patients with either anxiety or depression.
The MHD patients with both anxiety and depression
commonly had lower scores than any of the other three
groups of patients. Significantly lower scores in patients
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Table 2
KDQOL component scores according to anxiety and depression status in MHD patients and normal controls.
Items

MHD patients
AD

MHD patients
A+D

MHD patients
AD+

MHD patients
A+D+

P-value among
MHD patientsa

Normal controls
AD

n (male/female)
Age, years
Diabetic, %
ESRD-targeted areas
Effects of kidney disease
Burden of kidney disease
Dialysis staff encouragement
Patient satisfaction
Symptom problem list
Work status
Cognitive function
Quality of social interaction
Sexual functionf
Sleep
Social support
Overall health
SF-36 composite scores
Physical health composite score
Mental health composite score
Role physical
Pain
General health
Emotional well-being
Role emotional
Social function
Energy/fatigue

30 (18/12)
50.3 ± 13.8
23

14 (8/6)
54.5 ± 10.4
50

11 (10/1)
52.8 ± 12.6
36

17 (13/4)
53.6 ± 14.0
35

0.182
0.726
0.037

36 (20/16)
50.3 ± 12.6
0

76.4
54.7
80.0
79.4
89.5
35.0
93.6
89.6
89.3
72.3
85.6
68.3

±
±
±
±
±
±
±
±
±
±
±
±

20.9b
28.5b,c
22.2
17.3
9.6b,c
43.8
10.0b,c,d
12.2
18.3
17.3b
23.9
18.2b

75.7
50.0
85.7
80.9
74.1
21.4
78.6
81.9
79.7
63.0
94.1
67.1

±
±
±
±
±
±
±
±
±
±
±
±

17.7c
21.9
20.7
23.5
10.3b
32.3
15.5b
18.6
24.9
10.7c
15.4
19.0

58.2
27.3
80.7
77.3
87.7
31.8
75.8
83.0
50.0
62.7
80.4
60.9

±
±
±
±
±
±
±
±
±
±
±
±

28.5
19.0b
18.8
27.2
9.8d
40.5
24.5c
19.4
57.7
22.9d
26.7
23.9

40.3
27.6
58.7
55.9
62.5
29.4
69.4
68.6
62.5
36.5
64.8
50.0

±
±
±
±
±
±
±
±
±
±
±
±

20.1b,c
24.0c
22.9
22.8
17.3c,d
30.9
16.3d
19.8
10.2
16.5b,c,d
31.2
10.0b

0.002
0.025
0.090
0.570
0.003
0.963
0.015
0.361
0.090
0.002
0.064
0.022

96.3
81.9
92.2
88.1
95.5
79.0
86.7
81.1

±
±
±
±
±
±
±
±

4.1
27.1e
10.1
11.1
10.6
13.8
14.7
12.6

43.6
56.6
61.7
85.7
56.3
89.1
91.1
85.4
68.0

±
±
±
±
±
±
±
±
±

8.6
5.5b,c
40.3
17.3
20.0
8.8b,c
26.2
20.8b,c
19.7b

38.4
50.6
44.6
63.4
57.9
80.9
66.7
66.1
54.6

±
±
±
±
±
±
±
±
±

7.3
7.1d
42.9
18.6
15.5
11.7d
45.3
13.4b
14.2c

44.6
45.7
38.6
83.9
55.0
78.5
42.4
69.3
62.3

±
±
±
±
±
±
±
±
±

10.2
10.5b
49.2
29.8
19.4
16.0b,d
44.9
28.2
21.8d

33.7
43.4
19.1
57.4
34.7
60.6
56.9
54.4
35.3

±
±
±
±
±
±
±
±
±

8.8
12.4c,d
32.5
32.4
18.3
20.0c,d
45.3
24.2c
16.5b,c,d

0.308
0.008
0.535
0.228
0.140
0.001
0.968
0.004
0.014

53.3
53.9
91.0
86.0
76.5
83.3
92.6
91.7
74.6

±
±
±
±
±
±
±
±
±

4.8e
6.8
23.3
20.7
15.5e
15.5
22.7
12.0
14.5

Data are presented as mean ± standard deviation.
KDQOL: Kidney Disease and Quality of Life; MHD: maintenance hemodialysis; ESRD: end-stage renal disease; SF-36: 36-Item Short Form Health
Survey. AD means the subjects displaying neither anxiety nor depression, A+D+ means those displaying anxiety and depression, A+D means
those displaying anxiety but not depression, and AD+ means those displaying depression but not anxiety.
a
ANOVA analyses comparing different MHD patient groups according to anxiety and depression status adjusted for age, gender, presence of
diabetes, and dialysis vintage.
b,c,d
Pairwise comparisons (adjusted for age, gender, presence of diabetes, and dialysis vintage). Significantly different from values in other columns
with the same superscript (P < 0.05), as determined by a Tukey's honest significant difference test for pairwise comparisons.
e
Significantly different (P < 0.05) from MHD AD patients as determined by 2-tailed t-test adjusted for age, gender, and presence of diabetes.
f
n ¼ 14, n ¼ 8, n ¼ 4, n ¼ 4, and n ¼ 22 respondents for sexual function in MHD AD, A+D, AD+, A+D+ patients and AD normal
controls, respectively.

with both anxiety and depression were particularly
common for effects of kidney disease, symptom/problem list, sleep, emotional well-being, energy/fatigue,
and mental health composite score. The MHD patients
who had neither anxiety nor depression displayed
KDQOL scores that were rather similar to the normal
controls who did not have anxiety or depression (Table
2); the scores of these MHD patients were significantly
below normal scores only for work status, general
health, and physical health composite score (P < 0.05).
Association of physical activity with KDQOL score
The 7-day average DPA levels in MHD patients,
measured by the Actigraph® accelerometer, usually did

not correlate significantly with KDQOL ESRDtargeted or SF-36 scores after correlations were
adjusted for age, gender, diabetes, or dialysis vintage
(Table 3). Moreover, the associations that were statistically significant mostly became insignificant after
further adjustment for the anxiety and depression
scores, although the trends in the associations often
persisted. In the fully adjusted model, only 7-day
average DPA and the percent time spent in  moderate physical activity correlated with the role-physical
subscale; only percent time in moderate or greater
physical activity correlated with physical health composite score, and percent time in sleep or marked
inactivity correlated with dialysis staff encouragement
and patient satisfaction (Table 3).
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Table 3
Correlations between KDQOL components and daily physical activity measured by Actigraph® accelerometer and Human Activity Profile scores in
MHD patients (n ¼ 72).
KDQOL components

ESRD-targeted areas
Symptom-problem list
Effects of kidney disease
Burden of kidney disease
Work status
Cognitive function
Quality of social interaction
Sexual functiond
Sleep
Social support
Dialysis staff encouragement
Patient satisfaction
SF-36 composite scores
Physical health composite score
Mental health composite score
Role physical
Pain
General health
Emotional well-being
Role emotional
Social function
Energy/fatigue

Actigraph®
7-day average DPA

Actigraph®
Percent time in
moderate or greater
physical activity

0.07 (0.05)a
0.12 (0.01)
0.00 (0.09)
0.14 (0.15)
0.14 (0.04)
0.09 (0.02)
0.11 (0.08)
0.09 (0.04)
0.26c (0.21)
0.23 (0.17)
0.29c (0.23)

0.14 (0.02)
0.15 (0.04)
0.08 (0.01)
0.16 (0.18)
0.30 (0.22)
0.13 (0.05)
0.02 (0.03)
0.10 (0.04)
0.25c (0.20)
0.22 (0.15)
0.27c (0.21)

0.23 (0.19)
0.07 (0.05)
0.34b (0.29c)
0.06 (0.00)
0.09 (0.03)
0.25c (0.15)
0.16 (0.10)
0.05 (0.05)
0.19 (0.10)

0.29c (0.24c)
0.18 (0.07)
0.32b (0.27c)
0.14 (0.08)
0.14 (0.07)
0.27c (0.17)
0.26c (0.20)
0.22 (0.13)
0.24 (0.15)

Actigraph®
Percent time in
sleep or marked
inactivity

Human Activity
Profile
Maximum
activity score

Human Activity
Profile
Adjusted
activity score

Correlation Coefficients
0.11 (0.00)
0.16 (0.05)
0.01 (0.09)
0.04 (0.05)
0.14 (0.05)
0.16 (0.09)
0.16 (0.14)
0.16 (0.04)
0.29c (0.24)
0.30c (0.24c)
0.37b (0.32b)

0.23 (0.12)
0.25c (0.14)
0.16 (0.07)
0.06 (0.07)
0.24c (0.15)
0.04 (0.05)
0.14 (0.13)
0.26c (0.14)
0.20 (0.13)
0.16 (0.08)
0.21 (0.13)

0.35b (0.27c)
0.23 (0.13)
0.15 (0.06)
0.20 (0.22)
0.25c (0.17)
0.04 (0.14)
0.23 (0.18)
0.21 (0.08)
0.12 (0.05)
0.13 (0.05)
0.15 (0.07)

0.27c (0.23)
0.02 (0.12)
0.27c (0.22)
0.15 (0.09)
0.13 (0.07)
0.24c (0.14)
0.08 (0.01)
0.07 (0.04)
0.21 (0.11)

0.34b (0.30c)
0.32b (0.23)
0.28c (0.22)
0.21 (0.15)
0.31c (0.25c)
0.40b (0.33b)
0.18 (0.11)
0.23 (0.13)
0.43b (0.37b)

0.46b (0.42b)
0.30c (0.21)
0.36b (0.31c)
0.27c (0.22)
0.34b (0.29c)
0.36b (0.29c)
0.24c (0.17)
0.27c (0.19)
0.47b (0.41b)

KDQOL: Kidney Disease and Quality of Life; MHD: maintenance hemodialysis; DPA: daily physical activity; ESRD: end-stage renal disease; SF36: 36-Item Short Form Health Survey.
a
Correlation coefficients are adjusted for age, gender, presence of diabetes mellitus, and dialysis vintage.
b
P < 0.01, c0.01  P < 0.05, dn ¼ 30 respondents for sexual function component in maintenance hemodialysis patients.

Physical activity was also assessed by the Human
Activity Profile questionnaire. Maximum activity
scores correlated significantly with most of the SF-36
components, and adjusted activity scores correlated
with all SF-36 components in analyses adjusted for
age, gender, diabetes, and vintage; there were fewer
significant correlations with KDQOL ESRD-targeted
components (Table 3). After further adjustment for
anxiety and depression, far fewer of these associations
remained significant (Table 3). Perhaps the most
prominent were the persistence of the correlations
between maximum and adjusted activity scores and the
physical health composite score, general health,
emotional well-being and energy/fatigue.
Association of physical performance with KDQOL
scores
The three physical performance tests correlated
with few KDQOL-ESRD and SF-36 scores after
adjustment for age, gender, diabetes, and vintage
(Table 4). After further adjustment for anxiety and

depression, there were substantially fewer significant
associations, although again the trends in the associations persisted. The one exception was the large
number of sit-to-stand scores that correlated with SF36 scores. The fewest correlations were observed
with the stair-climbing test (Table 4).
Discussion
This study confirms previous reports that decreased
QOL as well as anxiety, depression, lower daily
physical activity (DPA), and reduced physical performance commonly occur in MHD patients.1,2,4,27e29
Our study also indicates that decreased QOL, reflected by low KDQOL scores, is significantly associated with anxiety, depression, and reduced DPA and
physical performance. The present study provides evidence that anxiety and depression, as measured by
BAI, BDI, and HADS, are associated with a decrease
in physical, mental, and ESRD-targeted elements of
QOL. These findings are consistent with several previous reports of an inverse association between anxiety
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Table 4
Correlations between KDQOL components and physical performance tests in MHD patients.
KDQOL components

6-Minute walk test

Sit-to-stand test

Stair climbing test

ESRD-targeted areas
Symptom-problem list
Effects of kidney disease
Burden of kidney disease
Work status
Cognitive function
Quality of social interaction
Sexual functiond
Sleep
Social support
Dialysis staff encouragement
Patient satisfaction
SF-36 composite scores
Physical health composite score
Mental health composite score
Role physical
Pain
General health
Emotional well-being
Role emotional
Social function
Energy/fatigue

Correlation
0.07 (0.01)a
0.09 (0.05)
0.06 (0.03)
0.22 (0.23)
0.08 (0.04)
0.18 (0.23)
0.06 (0.05)
0.00 (0.08)
0.09 (0.06)
0.30c (0.29c)
0.26c (0.24c)

Coefficients
0.35b (0.31c)
0.21 (0.14)
0.25c (0.19)
0.04 (0.04)
0.11 (0.13)
0.14 (0.22)
0.09 (0.09)
0.22 (0.14)
0.11 (0.06)
0.23 (0.18)
0.14 (0.08)

0.10 (0.19)
0.02 (0.09)
0.01 (0.03)
0.12 (0.11)
0.08 (0.04)
0.18 (0.24)
0.20 (0.14)
0.03 (0.11)
0.06 (0.10)
0.04 (0.01)
0.28c (0.26c)

0.26c (0.24)
0.21 (0.19)
0.34b (0.32b)
0.21 (0.19)
0.19 (0.17)
0.21 (0.18)
0.39b (0.38b)
0.05 (0.00)
0.27c (0.25c)

0.41b (0.38b)
0.15 (0.07)
0.28c (0.24c)
0.34b (0.30c)
0.29c (0.25c)
0.30c (0.24c)
0.10 (0.05)
0.17 (0.10)
0.38b (0.34b)

0.08 (0.11)
0.25c (0.23)
0.09 (0.06)
0.08 (0.12)
0.09 (0.06)
0.16 (0.12)
0.17 (0.14)
0.06 (0.12)
0.13 (0.09)

KDQOL: Kidney Disease and Quality of Life; MHD: maintenance hemodialysis; ESRD: end-stage renal disease; SF-36: 36-Item
Short Form Health Survey.
a
Correlation coefficients are adjusted for age, gender, presence of diabetes mellitus, and dialysis vintage. Correlation coefficients
in parentheses are further adjusted for anxiety and depression status.
b
P < 0.01, c0.01  P < 0.05, dn ¼ 30 respondents for sexual function component in maintenance hemodialysis patients.

and/or depression and QOL scores or overall perception of QOL in MHD patients.3,5,6
The current study also indicates that MHD patients
with both anxiety and depression display more
impaired QOL scores than patients who have either
anxiety or depression but not both (Table 2). The MHD
patients who have either anxiety or depression, but not
both, also tend to have more QOL scores that are lower
than in the patients who have neither anxiety nor
depression. Perhaps most strikingly, QOL scores of the
patients without anxiety or depression are usually not
different from normals. This finding suggests that
anxiety and depression are major causes of the reduced
QOL in MHD patients.
It should be remembered that the patients in this
study were selected to be a relatively healthy cohort of
MHD patients. Even the 23 out of 72 MHD patients
who had diabetes mellitus were relatively healthy, as
evidenced by their low Charlson comorbidity scores
and the fact that they had to satisfy the inclusion and
exclusion criteria in order to enter the study. These data
are consistent with the thesis that anxiety and depression are major determinants of the QOL of relatively
healthy MHD patients.

In the general adult population, there is a welldescribed positive correlation between DPA and
health-related quality of life (HRQOL).30,31 Several
studies have examined the relation between DPA or
physical performance and QOL in MHD patients. One
report from the dialysis outcomes and practice patterns
study (DOPPS) found that higher levels of selfreported aerobic, but not strength-building, physical
activity was positively associated with HRQOL.9
Almost all other reports examining the relationship
between physical activity and HRQOL in MHD patients are interventional. In one study, MHD patients
with low KDQOL physical health composite scores at
baseline showed substantial improvement in KDQOL
SF-36 component scores after 2 months of an individualized home exercise program involving strength,
flexibility, and aerobic exercises.8 Similarly, a study of
14 Korean MHD patients reported improved QOL in
these individuals after a 12-week aerobic exercise
program.7 However, one study found no change in
QOL, as determined by the KDQOL SF-36 physical
health composite scores and mental health composite
scores, after a 24-week intradialytic resistance training
program.32
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The present study is the first to our knowledge to
examine the cross-sectional associations between
objectively measured DPA, using a mechanical instrument that measures physical activity, and QOL
measures in MHD patients. DPA and physical performance measures correlated with several KDQOL
components. These correlative relationships also often
became weaker and statistically insignificant after adjustments for anxiety and depression; the exception to
this being the sit-to-stand test. It is noteworthy that
the Human Activity Profile scores correlated more
closely with the physical performance tests than with
accelerometer-measured DPA in our patients.4 This
may reflect the more subjective nature of the Human
Activity Profile, which is based upon the responder's
estimates and memory.
These data support the contention that the associations between DPA and many QOL scores are mediated to a substantial degree by the presence of anxiety
and depression. The foregoing considerations suggest
the possibility that effective prevention or treatment of
anxiety and depression in MHD patients may have
major benefits for both their QOL and daily physical
activity. Since depression, poor QOL scores, and low
DPA are also associated with increased hospitalization
and mortality rates in MHD patients,10e15 prevention
and treatment of depression and perhaps anxiety might
reduce morbidity and mortality in these individuals.
This study has several limitations. First, the sampling of different racial and ethnic groups was limited.
The sample size was relatively small, although many
significant associations were observed. The psychiatric
evaluation was limited to anxiety and depression only,
and this psychiatric assessment was restricted to the
BDI, BAI, and the HADS scales. Among the strengths
of this study, it is one of the few studies that have used
a validated instrument to measure DPA, and DPA was
measured for seven days. The fact that the MHD patients were relatively healthy facilitated our ability to
separate the effects of end-stage kidney disease and
MHD treatment on anxiety, depression, physical activity and performance, and quality of life from other
common comorbid conditions that afflict MHD patients, such as protein-energy wasting, severe heart
disease, strokes, or amputations. Finally, this study
included for comparison a normal sedentary control
group of similar age and gender ratio.
Conclusions
In relatively healthy MHD patients, anxiety and
depression are usually associated with a lower quality

of life and to a lesser degree daily physical activity and
physical performance. Among those MHD patients
who do not have anxiety or depression by standard
testing, quality of life scores appear to be normal.
These observations suggest the possibility that treatment of anxiety and depression may improve quality of
life, daily physical activity and some measures of
physical performance in MHD patients.
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